BiotechTube

Dupilumab Prefilled Syringe

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Nasal Polyps

Conditions

Nasal Polyps, Staphylococcus Aureus

Trial Timeline

Sep 1, 2022 → Dec 31, 2026

NCT ID
NCT05094570

About Dupilumab Prefilled Syringe

Dupilumab Prefilled Syringe is a approved stage product being developed by Regeneron Pharmaceuticals for Nasal Polyps. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05094570. Target conditions include Nasal Polyps, Staphylococcus Aureus.

What happened to similar drugs?

4 of 20 similar drugs in Nasal Polyps were approved

Approved (4) Terminated (2) Active (15)
🔄LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
✅Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
🔄xylo+dex nasal spray (0.1 mg+5 mg/dose) + NasicJohnson & JohnsonPhase 3
✅Budesonide NasalJohnson & JohnsonApproved
🔄Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroidAstraZenecaPhase 3
❌Benralizumab 30 mg + Matched placeboAstraZenecaPhase 3
🔄Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone FuroateAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05094570ApprovedRecruiting

Competing Products

20 competing products in Nasal Polyps

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
Rabeprazole 20 mg twice a day for 90-day period treatmentEisaiPhase 2
35
High dose of methotrexate + Gemcitabine + Pegaspargase + DexamethasoneEli LillyPhase 2
31
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Diphenhydramine 50 mg + Diphenhydramine 25 mg + Pseudoephedrine 120 mgJohnson & JohnsonApproved
43
xylo+dex nasal spray (0.1 mg+5 mg/dose) + NasicJohnson & JohnsonPhase 3
40
Budesonide NasalJohnson & JohnsonApproved
47
Diphenhydramine hydrochlorideJohnson & JohnsonPhase 1
29
SHR-1210Jiangsu Hengrui MedicinePhase 2
31
Experimental: Tezepelumab + Mometasone furoate or equivalent intranasal corticosteroidAstraZenecaPhase 3
40
Benralizumab 30 mg + Matched placeboAstraZenecaPhase 3
32
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone FuroateAstraZenecaPhase 3
40
Benralizumab + PlaceboAstraZenecaPhase 3
40
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
42
mometasone furoateMerckApproved
35
Fevipiprant 150 mg + Fevipiprant 450 mg + PlaceboNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 2
35
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40
Omalizumab + PlaceboRochePhase 3
40